Funding of new SFB/Transregio approved: The universities of Regensburg and Erlangen are collaborating with Fraunhofer Institutes to explore novel approaches to cancer therapy

Press Release / November 27, 2020

In the new Collaborative Research Center/Transregio (SFB/TRR) 305, scientists of the German universities of Regensburg and Erlangen and of the Fraunhofer-Gesellschaft will investigate the mechanisms of metastatic organ colonization and aim to develop novel systemic therapies. The Collaborative Research Center will be managed by the two co-spokesmen Prof. Christoph Klein, senior professor of Experimental Medicine and Therapy Research at the University of Regensburg and division director of Personalized Tumor Therapy at Fraunhofer ITEM, and Prof. Thomas Brabletz, senior professor of Experimental Medicine at the University of Erlangen-Nuremberg. Both have made internationally recognized contributions to metastasis research in the past few years and have received, among other awards, the German Cancer Prize. The German Research Foundation will be funding the SFB/TRR 305 with 11.7 million euros for a first funding period of four years.